Alzamend Neuro Debt
| ALZN Stock | USD 1.29 0.02 1.53% |
At this time, Alzamend Neuro's Net Debt To EBITDA is very stable compared to the past year. As of the 27th of November 2024, Interest Debt Per Share is likely to grow to 0.64, while Short and Long Term Debt Total is likely to drop about 174.9 K. With a high degree of financial leverage come high-interest payments, which usually reduce Alzamend Neuro's Earnings Per Share (EPS).
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.55 | Current Value 0.95 | Quarterly Volatility 1.12786825 |
Given that Alzamend Neuro's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Alzamend Neuro is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Alzamend Neuro to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Alzamend Neuro is said to be less leveraged. If creditors hold a majority of Alzamend Neuro's assets, the Company is said to be highly leveraged.
At this time, Alzamend Neuro's Total Current Liabilities is very stable compared to the past year. As of the 27th of November 2024, Change To Liabilities is likely to grow to about 2.1 M, while Liabilities And Stockholders Equity is likely to drop about 600 K. Alzamend |
Alzamend Neuro Bond Ratings
Alzamend Neuro financial ratings play a critical role in determining how much Alzamend Neuro have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Alzamend Neuro's borrowing costs.| Piotroski F Score | 4 | Poor | View |
| Beneish M Score | (24.88) | Unlikely Manipulator | View |
Alzamend Neuro Debt to Cash Allocation
As Alzamend Neuro follows its natural business cycle, the capital allocation decisions will not magically go away. Alzamend Neuro's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Alzamend Neuro currently holds 300.71 K in liabilities. Alzamend Neuro has a current ratio of 11.54, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Alzamend Neuro's use of debt, we should always consider it together with its cash and equity.Alzamend Neuro Total Current Liabilities Over Time
Alzamend Neuro Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Alzamend Neuro uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Alzamend Neuro Debt Ratio | 95.0 |
Alzamend Neuro Corporate Bonds Issued
Alzamend Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning Alzamend Neuro Use of Financial Leverage
Leverage ratios show Alzamend Neuro's total debt position, including all outstanding obligations. In simple terms, high financial leverage means that the cost of production, along with the day-to-day running of the business, is high. Conversely, lower financial leverage implies lower fixed cost investment in the business, which is generally considered a good sign by investors. The degree of Alzamend Neuro's financial leverage can be measured in several ways, including ratios such as the debt-to-equity ratio (total debt / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 345.8 K | 174.9 K | |
| Net Debt | -75.3 K | -79.1 K | |
| Short Term Debt | 345.8 K | 174.9 K | |
| Short and Long Term Debt | 270.6 K | 254.4 K | |
| Net Debt To EBITDA | 0.01 | 0.01 | |
| Debt To Equity | (0.10) | (0.11) | |
| Interest Debt Per Share | 0.46 | 0.64 | |
| Debt To Assets | 0.55 | 0.95 | |
| Total Debt To Capitalization | (0.15) | (0.14) | |
| Debt Equity Ratio | (0.10) | (0.11) | |
| Debt Ratio | 0.55 | 0.95 | |
| Cash Flow To Debt Ratio | (31.63) | (33.21) |
Pair Trading with Alzamend Neuro
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alzamend Neuro position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alzamend Neuro will appreciate offsetting losses from the drop in the long position's value.Moving together with Alzamend Stock
| 0.8 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.67 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.7 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Alzamend Stock
| 0.75 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.57 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.46 | MNOV | MediciNova | PairCorr |
| 0.45 | PHVS | Pharvaris BV | PairCorr |
| 0.43 | OPT | Opthea | PairCorr |
The ability to find closely correlated positions to Alzamend Neuro could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alzamend Neuro when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alzamend Neuro - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alzamend Neuro to buy it.
The correlation of Alzamend Neuro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alzamend Neuro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alzamend Neuro moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alzamend Neuro can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Alzamend Neuro Fundamentals Over Time. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (142.87) | Return On Assets (2.14) | Return On Equity (44.08) |
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.